This website uses cookies to ensure you get the best experience on our website. Learn more
A global problem
Every year, over 5 million people are diagnosed with cancer in their
digestive system.
Our unique approach combines expertise in gastrointestinal oncology, digital pathology and AI-driven biomarker discovery.
Every year, over 5 million people are diagnosed with cancer in their
digestive system.
One of the deadliest cancers occurs in the esophagus, with cases growing at an alarming rate.
9 out of every 10 affected patients are undiagnosed.
9 out of every 10 affected patients are undiagnosed.
Some patients with Barrett’s will develop advanced esophageal cancer and have a devastating five-year survival rate of less than 15%.
It is impossible to perform an invasive endoscopy on every patient at risk of esophageal cancer.
Our technologies give doctors access to less invasive and better diagnostics for diseases such as Barrett’s esophagus, so we can reduce deaths from late-stage cancer.
The Cytosponge test is a combination of a swallowable pill on a string for cell collection and a diagnostic test to identify patients at risk of esophageal cancer by detecting its precursor: Barrett’s Esophagus.
We provide histopathology as a service to public as well as private healthcare providers. Through our unique clinical pathway and data platform, we are positioned to change patient journeys by leveraging pathology data at scale.